Ind-Swift Laboratories Ltd. (INDSWFTLAB) AI Stock Analysis

• Market Cap: ₹7.45B
• Dividend Yield: N/A
• Average Volume (3M): 7.30K
• Price to Earnings (P/E): 3.0
• Beta (1Y): 1.33
• Revenue Growth: -68.96%
• EPS Growth: -30.30%
• Country: IN
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 73,486,860
• 10 Day Avg. Volume: 7,859
• 30 Day Avg. Volume: 7,299
• PEG Ratio: -0.04
• Price to Book (P/B): 0.46
• Price to Sales (P/S): 0.96
• P/FCF Ratio: -5.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 66 Neutral
• Price Target: ₹114.00 ▲(11.11% Upside)

Ind-Swift Laboratories Ltd. scores well due to its strong financial performance, particularly in revenue growth and balance sheet strength, despite cash flow challenges. The technical analysis supports a positive outlook, and the stock's low P/E ratio suggests it is undervalued. These factors collectively contribute to a solid overall stock score.

Ind-Swift Laboratories Ltd. Business Overview & Revenue Model

Company Description

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.

How the Company Makes Money

Ind-Swift Laboratories Ltd. generates revenue primarily through the sale of its pharmaceutical products, which include APIs and finished formulations. The company's revenue model is built on both domestic and international sales, with a significant portion of its earnings coming from exports to various countries. Key revenue streams include bulk drug sales to other pharmaceutical companies, direct sales of branded and generic medications, and contract manufacturing services. Additionally, strategic partnerships with other pharmaceutical firms, licensing agreements, and collaborations for research and development activities contribute to the company's earnings by expanding its market reach and enhancing its product portfolio.

Ind-Swift Laboratories Ltd. Financial Statement Overview

Summary

Ind-Swift Laboratories Ltd. demonstrates strong revenue growth and profitability, supported by a robust balance sheet with low leverage. However, significant cash flow challenges pose a risk, necessitating improved cash management strategies to sustain operations and growth.

Income Statement

Ind-Swift Laboratories Ltd. has shown a strong revenue growth rate of 25.63% in the latest year, indicating robust sales expansion. However, the company experienced a significant drop in EBIT, resulting in a negative EBIT margin for 2025. Despite this, the net profit margin remains healthy due to a substantial net income, suggesting effective cost management or one-time gains.

Balance Sheet

The balance sheet reflects a strong equity position with a low debt-to-equity ratio of 0.0178 in 2025, indicating financial stability and low leverage. The return on equity is impressive at 44.97%, showcasing efficient use of equity to generate profits. The equity ratio is solid, suggesting a stable financial structure.

Cash Flow

Cash flow analysis reveals challenges, with negative operating and free cash flows in 2025, indicating potential liquidity issues. The free cash flow growth rate is negative, suggesting declining cash generation capabilities. The ratios of operating and free cash flow to net income are unfavorable, highlighting cash flow management concerns.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.81B	5.62B	12.81B	12.07B	10.39B	8.91B
Gross Profit	3.48B	2.74B	4.13B	4.40B	4.10B	3.75B
EBITDA	2.87B	2.85B	7.82B	2.36B	2.39B	1.98B
Net Income	2.58B	2.50B	4.21B	475.97M	-21.49M	-31.47M
Balance Sheet
Total Assets	0.00	14.38B	14.60B	18.24B	18.01B	18.18B
Cash, Cash Equivalents and Short-Term Investments	4.67B	4.82B	4.94B	231.54M	333.68M	116.01M
Total Debt	0.00	408.41M	166.22M	8.62B	9.53B	10.05B
Total Liabilities	-11.73B	2.65B	6.48B	11.42B	12.00B	12.15B
Stockholders Equity	11.73B	11.73B	9.36B	6.82B	6.01B	6.04B
Cash Flow
Free Cash Flow	0.00	-898.80M	-2.08B	1.82B	1.32B	1.31B
Operating Cash Flow	0.00	-254.74M	-1.63B	1.95B	1.50B	1.35B
Investing Cash Flow	0.00	-1.10B	-1.23B	-133.68M	47.72M	-101.72M
Financing Cash Flow	0.00	692.05M	6.99B	-1.86B	-1.41B	-1.24B

Ind-Swift Laboratories Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 102.60
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDSWFTLAB, the sentiment is Neutral. The current price of 102.6 is above the 20-day moving average (MA) of 102.26, above the 50-day MA of 102.50, and above the 200-day MA of 97.42, indicating a bullish trend. The MACD of 0.40 indicates Negative momentum. The RSI at 48.77 is Neutral, neither overbought nor oversold. The STOCH value of 34.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:INDSWFTLAB.

Ind-Swift Laboratories Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	69 Neutral	₹6.06B	11.28	―	―	9.15%	88.32%
INDSWFTLAB	66 Neutral	₹7.45B	2.95	―	―	-68.96%	-30.30%
SAKAR	64 Neutral	₹7.72B	39.03	―	―	21.65%	73.16%
MEDICAMEQ	59 Neutral	₹4.41B	49.73	―	0.27%	-9.90%	33.18%
ZIMLAB	56 Neutral	₹3.35B	35.37	―	―	-3.36%	-47.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NECLIFE	43 Neutral	₹3.11B	30.02	―	―	-3.41%	-3028.44%

Ind-Swift Laboratories Ltd. Corporate Events

Ind-Swift Laboratories Announces 30th AGM and Annual Report Availability

Ind-Swift Laboratories Ltd. has announced the scheduling of its 30th Annual General Meeting (AGM) on September 29, 2025, which will be conducted via video conferencing in compliance with regulatory guidelines. The company has also made its Annual Report for the financial year 2024-25 available online, ensuring transparency and accessibility for stakeholders. This move highlights Ind-Swift’s commitment to maintaining open communication with its shareholders and adhering to regulatory requirements, potentially strengthening its position in the market.

Ind-Swift Laboratories Announces Major Share Allotment Amid Amalgamation

Ind-Swift Laboratories Ltd. has announced the allotment of over 8.1 million equity shares as part of a Scheme of Arrangement for the amalgamation with Ind-Swift Limited. This strategic move is expected to streamline operations and enhance market positioning by consolidating resources and expanding shareholder value. The newly allotted shares will be listed on stock exchanges once necessary permissions are obtained, indicating a significant step in the company’s growth trajectory.

Ind-Swift Laboratories Announces Financial Results and Share Allotment Post-Merger

Ind-Swift Laboratories Ltd. announced the approval of its audited financial results for the fourth quarter and fiscal year ending March 31, 2025, during a board meeting held on August 11, 2025. The results, reviewed by the Audit Committee and audited by Rattan Kaur & Associates, reflect the company’s financial performance post-merger with Ind Swift Limited. Additionally, the board approved the allotment and redemption of 1% Redeemable Preference Shares as part of the amalgamation scheme. These developments are expected to impact the company’s financial structure and stakeholder interests positively.